Chemists synthesize fungal compound with anti-cancer activity

April 26, 2009 Anne Trafton,

Structural diagram of (+)-11,11'-Dideoxyverticillin A. MIT chemists recently synthesized the compound, which has shown anti-cancer activity, for the first time. Graphic courtesy Mohammad Movassaghi
( -- Ten years ago, William Fenical of the Scripps Institution of Oceanography isolated from an ocean-living fungus a compound that has since shown the ability to kill cancer cells in the lab. Now, for the first time, MIT chemists have synthesized the compound, an advance that could open the door to new drug treatments for cancer.

The compound, known as (+)-11,11'-Dideoxyverticillin A, is one of the most structurally complex members of a family of naturally occurring .

Mohammad Movassaghi, associate professor of chemistry, graduate student Justin Kim and former postdoctoral associate James Ashenhurst reported the synthesis in the April 10 issue of Science.

Their 11-step synthesis, which starts with commercially available , provides ample quantities of the natural alkaloids and gives access to a wide range of related , enabling thorough biological evaluation of these types of alkaloids as anticancer agents.

"If you want to only rely on the natural substance, you often have to go back to the natural source and extract more material for further study. This is certainly OK if getting to the natural source is easy and if the extraction yield is acceptable," said Movassaghi. "However, with a chemical synthesis you can rely on commercially available starting material, scale up the synthesis as needed, and make designed derivatives of the compound of interest."

Movassaghi said his team was drawn to the compound not just for its anti-cancer potential but also for its fascinating . The (+)-11,11'-Dideoxyverticillin A molecule has 10 rings and eight stereogenic centers, or that have four different chemical groups attached to them.

"Because of the interesting structures, these compounds provide an ideal arena for exploring and developing new chemistry," said Movassaghi. "As you try to make the molecule, you become aware of its chemistry and oftentimes it's very informative in terms of it's possible mode of action."

When carbon atoms have four different groups attached to them, they can take on two possible arrangements, which are mirror images of each other. Producing the correct arrangement for all stereocenters was particularly challenging, said Movassaghi.

As large chemical structures are attached to each carbon, it also becomes more difficult to perform additional reactions at the same carbon atom, because the extra bulk makes the carbon less accessible.

Movassaghi says that while each step of the synthesis was difficult to figure out, the hardest task was designing the overall order of the synthesis. The molecule has several bonds that are very sensitive to oxidation or cleavage, so each reaction must occur in a precise order that will not expose those bonds to degradation.

"Justin and James had the solutions to each of the independent steps much earlier, but the major challenge was recognizing what would be the optimal sequence for each of these events to occur," said Movassaghi.

Now that the chemical has been demonstrated, researchers can tinker with it to produce similar compounds that may also have potential pharmacological activity.

The natural function of (+)-11,11'-Dideoxyverticillin A is not known, but it is likely to be involved in either natural defense or signaling mechanisms -- "chemical warfare at the microbial level," as Movassaghi describes it.

In other words, a colony of fungus might secrete the substances, toxic to competing species, to prevent invaders from stealing the same food and other resources.

"While the natural source may use this compound for defense or signaling, other scientists have shown this compound as having potential for treatment of cancer due to its antiangiogenic activity and efficacy against human breast cancer cell lines," Movassaghi said.

Movassaghi is an Alfred P. Sloan Research Fellow and a Beckman Young Investigator. The research was supported in part by non-restricted funds from Amgen, AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Merck and Lilly.

Provided by Massachusetts Institute of Technology (news : web)

Explore further: Chemists synthesize herbal alkaloid

Related Stories

Chemists synthesize herbal alkaloid

April 15, 2009

The club moss Lycopodium serratum is a creeping, flowerless plant used in homeopathic medicine to treat a wide variety of ailments. It contains a potent brew of alkaloids that have attracted considerable scientific and medical ...

Periwinkle can serve as tiny chemical plant

November 16, 2006

MIT researchers have discovered a way to manipulate the chemistry taking place in the tiny periwinkle plant to produce novel compounds that could have pharmacological benefits.

Recommended for you

3-D culturing hepatocytes on a liver-on-a-chip device

January 17, 2019

Liver-on-a-chip cell culture devices are attractive biomimetic models in drug discovery, toxicology and tissue engineering research. To maintain specific liver cell functions on a chip in the lab, adequate cell types and ...

This computer program makes pharma patents airtight

January 17, 2019

Routes to making life-saving medications and other pharmaceutical compounds are among the most carefully protected trade secrets in global industry. Building on recent work programming computers to identify synthetic pathways ...

Cultivating 4-D tissues—the self-curving cornea

January 17, 2019

Scientists at Newcastle University have developed a biological system which lets cells form a desired shape by moulding their surrounding material—in the first instance creating a self-curving cornea.


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.